tweenvest

Braveheart Bio, Inc. (NasdaqGM: BRVE)

Health Care · Pharmaceuticals · US

$19.49

-0.66% today · -34.6% 1Y

Public summary
A free snapshot of Braveheart Bio, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Braveheart Bio, Inc. (NasdaqGM: BRVE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.59B and employs 49 people.

Over the last twelve months the share price has lost 34.6%, trading between 17.42 and 32.00.

Tweenvest scores Braveheart Bio, Inc. across four factors: quality 78/100, value 100/100. Its strongest factor is value.

BRVE price history

Aug 7, 2026 · 30.00Weekly closes 18.60 – 30.00Nov 16, 2026 · 19.49

Key figures

Market cap
$1.59B
Revenue (TTM)
—
P/E
-16.78
EPS
-8.20
Dividend yield
—
Beta (5Y)
—
52-week high
$32.00
52-week low
$17.42
Avg volume (3M)
—
Shares outstanding
81.63M
Employees
49
Next earnings
—

About Braveheart Bio, Inc.

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

ISIN
US10567X1019
Founded
2024
Listed since
Aug 6, 2026
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
Jubilant Pharmova LimitedBSE: 530019$1.62BRs965.10-1.74%
Mayinglong Pharmaceutical Group Co., Ltd.SHSE: 600993$1.61BCN¥24.89+2.22%
Shanghai Shyndec Pharmaceutical Co., Ltd.SHSE: 600420$1.60BCN¥7.97-1.24%
Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287$1.60BCN¥18.79+0.54%
Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572$1.57BCN¥4.12-0.48%
Fujian Haixi Pharmaceuticals Co., Ltd.SEHK: 2637$1.57BHK$156.00-0.32%
Vigonvita Life Sciences Co., Ltd.SEHK: 2630$1.55BHK$72.65-3.13%
Marksans Pharma LimitedNSEI: MARKSANS$1.53BRs318.50-0.47%

Browse every Pharmaceuticals company →